Potential indications for liver transplant in Child–Pugh A and Model for End‐stage Liver Disease exception for hepatocellular carcinoma in Japan
- 3 March 2025
- journal article
- Published by Wiley in Hepatology Research
- Vol. 55 (6) , 896-907
Abstract
Aim: In 2019, expanded criteria for hepatocellular carcinoma (HCC), known as 5‐5‐500 (size ≤5 cm, number ≤5, alpha‐fetoprotein ≤500 ng/mL), as well as Model for End‐stage Liver Disease (MELD) exception, were implemented in Japan. In the present study, we evaluated liver transplantation indications and the Japanese allocation policy for HCC.Methods: Adults with HCC were evaluated between January 2013 and December 2017 in a multicenter study in Japan. The patients were aged ≤65 years, in line with the limits of Japanese transplant center limits.Results: HCC patients (n = 289) were classified as Child–Pugh A (74%), B (18%), or C (8%). Of these, 178 (62%) and 185 (64%) met the Milan and 5‐5‐500 criteria, respectively. The respective 1‐ and 5‐year overall survival rates of patients who met the criteria were 100% and 88.1% in Child–Pugh A, 91.7% and 30.6% in B, and 72.9% and 0% in C without access to liver transplantation. For Child–Pugh A patients, we developed a risk score using the Child–Pugh score, des‐gamma‐carboxy prothrombin, tumor‐node‐metastasis stage grade, as well as albumin‐bilirubin and albumin‐bilirubin tumor‐node‐metastasis stage , which predicted worse prognosis. Additionally, we showed the characteristics of patients who achieved MELD exception points high enough to receive an organ: survival at least 2 years after waitlist registration, relatively good liver functional reserve, and sufficient tumor control with multiple treatments.Conclusions: High‐risk patients, identified by our scoring system and albumin‐bilirubin tumor‐node‐metastasis stage ≥2 in Child–Pugh A, should be considered for liver transplantation eligibility. The allocation policy for HCC should be revised based on precise evaluations on a regular basis.Keywords
Funding Information
- Japan Society for the Promotion of Science
This publication has 27 references indexed in Scilit:
- Global Epidemiology and Genetics of Hepatocellular CarcinomaGastroenterology, 2023
- Patients with liver cirrhosis due to nonalcoholic steatohepatitis have lesser chances for liver transplantationJournal of Hepato-Biliary-Pancreatic Sciences, 2022
- BCLC strategy for prognosis prediction and treatment recommendation: The 2022 updateJournal of Hepatology, 2021
- Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSOAnnals of Oncology, 2020
- The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National LevelJAMA Oncology, 2017
- Liver transplantation in JapanLiver Transplantation, 2016
- Comparison of Liver Transplant–Related Survival Benefit in Patients With Versus Without Hepatocellular Carcinoma in the United StatesGastroenterology, 2015
- Excess mortality on the liver transplant waiting list: Unintended policy consequences and model for End‐Stage Liver Disease (MELD) inflationHepatology, 2014
- Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinomaLiver Transplantation, 2008
- Extending indicationLiver Transplantation, 2007